Havey Cardio is setting a new global standard in cardiovascular and cerebrovascular screening through our proprietary Pulse Wave Transit Time Ratio (PWTTR) analysis technology.

1. Technological Innovation: Unmatched Precision – Traditional Pulse Wave Velocity (PWV) methods often suffer from measurement errors depending on the patient’s body type or the practitioner’s technique. We have overcome these limitations by developing a technology that analyzes pulse wave data based on time ratios alone, eliminating the need for distance measurements. This breakthrough has been clinically validated, achieving a high diagnostic accuracy of approximately 82% in sensitivity and specificity.
2. Practical Innovation: Accessibility and Ease of Use – Equipped with our self-developed, high-sensitivity digital pressure sensors, our solution enables the simultaneous, accurate, and convenient measurement of pulse waves from multiple body points. We provide an environment where cardiovascular health can be managed easily not only in specialized general hospitals but also in primary care clinics, making preventive screening more accessible than ever.
3. Future Innovation: Synergy Between AI and Expertise – Our robust R&D ecosystem is led by executives with extensive experience in the pharmaceutical and healthcare industries, alongside a dedicated team of Ph.D. researchers in biomedical engineering. We are currently advancing a next-generation diagnostic platform that utilizes Artificial Intelligence (AI) simulations to detect subtle anomalies in pulse wave signals.

Our Vision Following our certification as a Venture Business and the official recognition of our Industrial R&D Center in 2025, Harvey Cardio is now poised for a major leap forward. Our mission is clear: to contribute to global health by developing innovative methods for the early detection and prevention of cardiovascular diseases, ensuring a healthier life for all humanity.